

2-2021

## Retrospective Chart Review of Metastatic Solid Tumor Discharges to Subacute Rehab

Sarah Svetec

*Thomas Jefferson University, sarah.svetec@students.jefferson.edu*

Molly Hanson, CRNP

*Thomas Jefferson University, molly.hanson@jefferson.edu*

Brooke Worster, MD

*Thomas Jefferson University, brooke.worster@jefferson.edu*

Follow this and additional works at: [https://jdc.jefferson.edu/si\\_phr\\_2023\\_phase1](https://jdc.jefferson.edu/si_phr_2023_phase1)



Part of the [Public Health Commons](#)

**[Let us know how access to this document benefits you](#)**

---

### Recommended Citation

Svetec, Sarah; Hanson, CRNP, Molly; and Worster, MD, Brooke, "Retrospective Chart Review of Metastatic Solid Tumor Discharges to Subacute Rehab" (2021). *Phase 1*. Paper 3.

[https://jdc.jefferson.edu/si\\_phr\\_2023\\_phase1/3](https://jdc.jefferson.edu/si_phr_2023_phase1/3)

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's [Center for Teaching and Learning \(CTL\)](#). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Phase 1 by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: [JeffersonDigitalCommons@jefferson.edu](mailto:JeffersonDigitalCommons@jefferson.edu).

# Retrospective Chart Review of Metastatic Solid Tumor Discharges to Subacute Rehab

Sarah Svetec, Molly Hanson CRNP\*, Brooke Worster MD

# Introduction and Objective

- **Background:** regaining strength through subacute rehabilitation (SAR) as a mechanism to return cancer patients to therapy is poorly understood
- **Rationale:** provide realistic advice to patients when cancer-directed therapy must be stopped
- **Inquiry question:** what are cancer patients able to accomplish following referral to SAR?
  - ***Hypothesis:*** majority of patients will not return to cancer-directed therapy following SAR; high functional status at discharge will be the best predictor of return

# Methods

- **Population:** metastatic solid tumor patients discharged to SAR (2018-2020)
  - *Partnership:* Neu Center Research Team
- **Collection methods:** retrospective chart review
- **Main predictors & outcomes:**
  - Primary outcome = patient return to anti-cancer therapy
  - Main predictor = PT functional status score (AMPAC)
- **Analysis:** descriptive statistics of patient outcomes + logistic regression of AMPAC score and return to therapy

# Results

- Results are pending!

- ***Example results:***

Only 31 of the 112 patients (28%) returned to cancer-directed therapy within 60 days of discharge to SAR. Functional status score was positively associated with return to cancer-directed therapy. The average survival for patients was 36 days from original discharge and 40% of patients were readmitted to the hospital within 30 days.

# Conclusions

- **Potential impact:** guidance to patients during difficult turning point in care
- **Limitations:** sample only includes SKCC patients, decision is highly individual
- **Next steps:** receive data through EPIC extraction → run analysis with statistician → assist in writing paper

# Disclosures and Acknowledgements

- Thank you to PHR SI track for your flexibility!
- Thank you to NEU Center Research Team, especially Molly Hanson, Preethi Selvan, Brooke Worster, and Amy Leader!



**Jefferson**

Philadelphia University +  
Thomas Jefferson University

---

HOME OF SIDNEY KIMMEL MEDICAL COLLEGE